REG - Spectral MD Holdings - Total Voting Rights

Spectral MD HoldingsAnnouncement

03/02/2023 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230203:nRSC9261Oa&default-theme=true

RNS Number : 9261O  Spectral MD Holdings, Ltd.  03 February 2023

3 February 2023

Spectral MD Holdings, Ltd.

        ("Spectral MD" or the
"Company")

 

Total Voting Rights

 

LONDON, U.K. AND DALLAS, TX, U.S. - Spectral MD Holdings, Ltd. (AIM: SMD), a
predictive analytics company with proprietary AI algorithms and optical
technology for faster and more accurate treatment decisions in wound care,
announces that, as at the date of this announcement, there are 136,201,515
ordinary shares of Common Stock of US $0.001 each ("Shares") in issue, with
one voting right per Share. This follows the issue of 104,451 Shares in
January in satisfaction of option exercises and in accordance with the
Company's block listing, details of which were announced on 7 November 2022.

 

The total number of voting rights in the Company is therefore 136,201,515.

 

This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the issued share capital of the
Company under the Company's Certificate of Incorporation. No Common Stock is
held in treasury.

 

 

 

 

For further information please contact:

 

 Spectral MD Holdings, Ltd.                        investors.spectralmd.com
 Wensheng Fan, Chief Executive Officer             via Walbrook PR
 Nils Windler, Chief Financial Officer

 SP Angel Corporate Finance LLP (NOMAD and Joint Broker)                                             Tel: +44 (0)20 3470 0470
 Stuart Gledhill/Harry Davies-Ball (Corporate Finance)

 Vadim Alexandre/Rob Rees (Sales & Broking)

 Stifel Nicolaus Europe Limited (Joint Broker)     Tel: +44 (0)20 7710 7600

 Charles Hoare / Ben Maddison / Nick Harland

 Will Palmer-Brown

 Walbrook PR Ltd (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com
 Paul McManus / Louis Ashe-Jepson /                Mob: +44 (0)7980 541 893 / +44 (0)7747 515 393

 Sam Allen                                         +44 (0)7502 558 258

 

About Spectral MD:
 

We are a dedicated team of forward-thinkers striving to revolutionize the
management of wound care by "Seeing the Unknown" ® with our DeepView(®)
Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREAKADEAFDEFA